Patent SG-11201808996S-A (SG)
Title: Orally disintegrating tablets
Inventor: AL HUSBAN FARHAN ABDEL KARIM MOHAMMAD
IPC: B65D75/36
Filed: 2017-04-20
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 111111101111 0 DOI 010111110101111 0 111 0111011H111111111111111111111111 Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\"\" WO 2017/182589 Al 26 October 2017 (26.10.2017) WIPO I PCT (51) International Patent Classification: EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, A61K 9/20 (2006.01) B65D 75/36 (2006.01) MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, A61K 31/519 (2006.01) A61P 9/10 (2006.01) TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, A61J 1/03 (2006.01) KM, ML, MR, NE, SN, TD, TG). (21) International Application Number: PCT/EP2017/059443 Published: — with international search report (Art. 21(3)) (22) International Filing Date: — before the expiration of the time limit for amending the 20 April 2017 (20.04.2017) claims and to be republished in the event of receipt of (25) Filing Language: English amendments (Rule 48.2(h)) (26) Publication Language: English (30) Priority Data: 62/325,584 21 April 2016 (21.04.2016) US (71) Applicant: ASTRAZENECA AB [SE/SE]; SE-151 85 Sodertalje (SE). (72) Inventors: AL HUSBAN, Farhan Abdel Karim Mo- hammad; AstraZeneca, Redesmere F42B, Silk Road Busi- _ ness Park, Charter Way, Macclesfield Cheshire SK10 2NA (GB). GLAD, Lars Hakan Christer; AstraZeneca, SE-431 — 83 Molndal (SE). HALLSTEIN, Jenny Malin Christi- na; Vastra Eklanda Hojd 23, SE-431 59 Molndal (SE). = MOIR, Andrea Jane; AstraZeneca, Redesmere UG18, Silk =_ Road Business Park, Macclesfield, Cheshire SK10 2NA = (GB). THOMPSON, Michael Peter; 7 Calderbrook Court, Meadowbrook Way, Cheadle Hulme, Cheshire SK8 5NX = (GB). = Agent: CARLING, David Andrew; Potter Clarkson LLP, The Belgrave Centre, Talbot Street, Nottingham NG1 5GG (74) = (GB). Designated States (unless otherwise indicated, for every (81) kind of national protection available): AE, AG, AL, AM, = _ AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, = CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, = DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, = = MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, = — PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, = SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, — TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = Designated States (unless otherwise indicated, for every (84) kind of regional protection available): ARIPO (BW, GH, = 1-1 GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, Ot in ei of (54) Title: ORALLY DISINTEGRATING TABLETS 1-1 ---- (57) : The present invention relates to rapidly disintegrating oral dosage forms, more particularly to rapidly disintegrating IN tablets containing (1S,2S,3R,5S)-3-[7- { [(1R,2S)-2-(3,4- difluorophenypcyclopropyl] amino 1 -5-(propylthio)-3H41,2,3] -triazolo [4,5- 0::) d]pyrimidin-3-y1]-5 5-(2-hydroxyethoxy)cyclopentane-1,2-diol and a disintegrating excipient. Blister packs suitable for use with the N rapidly disintegrating oral dosage form are also disclosed. C